No Cardiac Benefit for Omega-3 Fatty Acids

Article

A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.

A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.

The RCTs included omega-3 administration and diet or placebo for primary or secondary cardiovascular disease (CVD). Studies with treatment duration less than 1 year were excluded to ensure sufficient time to prove efficacy of treatment in CVD prevention. The researchers also evaluated the methodological quality of the trials and assessed the risk of bias, using the Cochrane collaboration tool.

Most of the study participants were of European ancestry (15 studies; 49,314 participants) but the largest trial included 18,645 Japanese participants. In all but two trials, omega-3 supplements were used, at a mean dosage of 1.51 g/day; mean treatment duration was 2 years.

When all supplement studies were considered, no statistically significant association was observed for all-cause mortality (relative risk [RR], 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003, 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), or stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004). Neither study-specific nor population-specific characteristics were associated with the observed effect of omega-3.

Read other articles in this issue of Special Delivery.

Recent Videos
Revi System shows efficacy against urgency urinary incontinence | Image Credit: ics.org.
1 expert is featured in this series.
Researchers highlight risks of breastfeeding while taking Levetiracetam | Image Credit: uwaterloo.ca.
Ipek Ensari, PhD, highlights improved mental health in chronic pelvic pain from physical activity | Image Credit: scholars.mssm.edu
New pSNM system empowers patients in urge urinary incontinence treatment | Image Credit: trinityhealthmichigan.org.
Jannah Thompson, MD, highlights battery free device for UUI management | Image Credit: trinityhealthmichigan.org
Anietie Aliu, PhD, highlights racial barriers to breast cancer screening | Image Credit: bbc.com.
Anietie Aliu, PhD, discusses how to improve breast cancer screening disparities | Image Credit: bbc.com
Jennifer Payne, MD, highlights how to help young women with perimenopause symptoms | Image Credit: uvahealth.com/findadoctor.
Perimenopausal symptoms in young women discussed by Jennifer Payne, MD | Image Credit: uvahealth.com/findadoctor.
Related Content
© 2025 MJH Life Sciences

All rights reserved.